医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Catalent Announces Major China Expansion with Two New Facilities for Softgel Technologies and Clinical Supply Solutions Businesses

2013年03月11日 PM10:25
このエントリーをはてなブックマークに追加


 

SOMERSET, N.J.

Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, today announced two joint ventures in China for its Softgel Technologies and Clinical Supply Solutions businesses. Catalent continues to expand its global leadership by providing access to drug delivery and clinical trial capabilities for customers in Asia Pacific. The company intends to make additional investments in these two facilities over the next several years to broaden its offerings in the Chinese market.

First, Catalent has agreed to acquire, pending regulatory approvals, a majority share in Haining-based, privately held Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd. The business produces nutritional softgel products for Chinese and Asia Pacific markets, and employs 120 staff. Catalent intends to work with regulators for future expansion into OTC and prescription softgel manufacturing in China.

In the second announcement, Catalent and ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, have formed a joint-venture called Catalent (Shanghai) Clinical Trial Supplies Co., Ltd. A new 31,000 sq ft facility in Shanghai, which is currently under construction, will be the first in China to provide end-to-end solutions for clinical trial supplies, including comparator sourcing, primary and secondary packaging and labeling, and storage and distribution.

Commenting on both investments, Catalent’s President & CEO, John Chiminski said, “As part of our growth strategy, these initial steps enable us to better serve the important Chinese market for both global and domestic customers. Our clients and their patients will benefit from access to Catalent’s advanced technologies and solutions, together with best-in-class innovation, reliable supply and quality compliance.”

We are delighted to be working with Catalent, a world leader in drug development services and clinical supply services,” said Michael Hui, founder and CEO of ShangPharma. “This cooperation will enable both ShangPharma and Catalent to better serve our multinational pharmaceutical customers through tailored, integrated solutions.”

The Chairman & CEO of Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd, Jiang Renfei commented “The combination of Catalent’s unparalleled track record of Softgel innovation and commercial success, and our deep understanding of the local market, will provide extensive benefits for our customers.

No other terms of the transactions have been disclosed.

About Catalent

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.

more products. better treatments. reliably supplied.™

About ShangPharma Corporation

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma’s services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

About Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd.,

Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd., located in Haining, Zhejiang Province, China, is specializing in producing nutritional softgel products. The company has been serving customers in China and Asia Pacific region since 2007.

CONTACT

Catalent Global:
Elliott Berger, +1-917-650-3132
elliott.berger@catalent.com
Catalent
Europe:
Chris Halling, +44 (0) 7580 041073
Chris.halling@catalent.com
ShangPharma
China:
Josh Gartner, +86 (10) 5960 8600
shangpharma@brunswickgroup.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024